文献速递肝病消化道肿瘤与早癌

T细胞衔接抗体可控制HBV感染并靶向HBsAg阳性肝癌

T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
PubMed 文献 · J Hepatol · 2021-06-23

该研究构建了同时结合HBV包膜蛋白与T细胞CD3或CD28的双特异性T细胞衔接抗体,在体外可协同激活T细胞、杀伤感染细胞并经非细胞溶解机制控制HBV;在免疫缺陷小鼠中可招募T细胞至HBVenv阳性肿瘤并减少肿瘤负荷。

要点

  • 双特异性T细胞衔接抗体可同时结合HBV包膜蛋白与T细胞CD3或CD28。
  • 两种抗体协同激活多功能T细胞,兼具杀伤感染细胞与细胞因子介导的抗病毒作用。
  • 小鼠体内可招募T细胞至HBVenv阳性肿瘤并减少肿瘤负荷。

核心结论

  • 给予靶向HBVenv的T细胞衔接抗体可促使T细胞重新定向至HBV阳性靶细胞,为慢性乙肝和HBV相关肝癌提供可行且有前景的治疗思路。

研究设计与样本

  • 构建同时结合HBV包膜蛋白与T细胞CD3或CD28的双特异性T细胞衔接抗体。
  • 体外将T细胞衔接抗体与健康供者淋巴细胞及HBV感染靶细胞共培养,检测促炎细胞因子、细胞毒效应和抗病毒效果。
  • 体内将HBVenv阳性与阴性肝癌细胞移植至免疫缺陷小鼠,研究疗效。

主要发现

  • 两种T细胞衔接抗体协同激活T细胞成为多功能效应细胞。
  • 激活的T细胞通过杀伤感染细胞产生强抗病毒效应,并通过非细胞溶解、细胞因子介导机制控制HBV。
  • 小鼠体内抗体将T细胞特异性吸引至表达HBVenv的肿瘤,导致T细胞激活、肿瘤浸润和肿瘤负荷减少。

临床怎么用

  • 该策略可能用于恢复慢性乙肝患者抗病毒T细胞免疫,并为HBV相关肝癌提供靶向T细胞治疗思路。

局限性

  • 体内证据来自免疫缺陷小鼠移植瘤模型,尚需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Current antiviral therapies control but rarely eliminate HBV, leaving chronic HBV carriers at risk of developing hepatocellular carcinoma (HCC). Lacking or dysfunctional virus-specific adaptive immunity prevents control of HBV and allows the virus to persist. Restoring antiviral T-cell immunity could lead to HBV elimination and cure of chronically infected patients. METHODS: We constructed bispecific T-cell engager antibodies that are designed to induce antiviral immunity through simultaneous binding of HBV envelope proteins (HBVenv) on infected hepatocytes and CD3 or CD28 on T cells. T-cell engager antibodies were employed in co-cultures with healthy donor lymphocytes and HBV-infected target cells. Activation of the T-cell response was determined by detection of pro-inflammatory cytokines, effector function (by cytotoxicity) and antiviral effects. To study in vivo efficacy, immune-deficient mice were transplanted with HBVenv-positive and -negative hepatoma cells. RESULTS: The 2 T-cell engager antibodies synergistically activated T cells to become polyfunctional effectors that in turn elicited potent antiviral effects by killing infected cells and in addition controlled HBV via non-cytolytic, cytokine-mediated antiviral mechanisms. In vivo in mice, the antibodies attracted T cells specifically to the tumors expressing HBVenv resulting in T-cell activation, tumor infiltration and reduction of tumor burden. CONCLUSION: This study demonstrates that the administration of HBVenv-targeting T-cell engager antibodies facilitates a robust T-cell redirection towards HBV-positive target cells and provides a feasible and promising approach for the treatment of chronic viral hepatitis and HBV-associated HCC. LAY SUMMARY: T-cell engager antibodies are an interesting, novel therapeutic tool to restore immunity in patients with chronic hepatitis B. As bispecific antibodies, they bind envelope proteins on the surface of the hepatitis B virus (HBV) and CD3 or CD28 on T cells. This way, they induce a potent antiviral and cytotoxic T-cell response that leads to the elimination of HBV-positive cells. These bispecific T-cell engager antibodies are exciting therapeutic candidates for chronic hepatitis B and HBV-associated hepatocellular carcinoma.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Quitt O, Luo S, Meyer M, et al. T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice. J Hepatol. 2021. PMID: 34171437. doi:10.1016/j.jhep.2021.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。